Assure Holdings Reports Second Quarter 2023 Financial Results
DENVER, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
Month: August 2023
Nextech Launches New Med Spa Software that Drives Facility Growth in a Rapidly Evolving Industry
TAMPA, Fla., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Nextech, a complete healthcare technology solution for specialty providers, announced today the...
CYCLE Kids Launches Brooklyn-Based Fundraising Campaign
Non-profit to Kick Off Back-to-School Campaign with a Times Square Billboard on National Non-Profit Day CYCLE Kids A Bike Can...
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned...
Akari Therapeutics, Plc Announces ADS Ratio Change
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading...
Carhartt Inc. and CorVel Corporation Named Risk Management Team of the Year in 2023 U.S. Insurance Awards
FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Carhartt Inc., one of America’s leading manufacturers of durable workwear and...
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients...
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseasesBOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:...
Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a...
Interactive Strength Inc. (Nasdaq: TRNR d/b/a “FORME”) Announces Non-Binding Letter of Intent and Exclusivity Agreement to Acquire a Connected Fitness Equipment Business
The combined Company is projected to generate more than $25 million in gross revenue in 2024 and be cashflow positive...
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or...
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE...
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
DAS Health Celebrates 11th Win on the Inc. 5000 List of Fastest-Growing Companies
Tampa, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- DAS Health, a leading provider of health IT and management solutions, is...
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success...
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH),...
Milestone Scientific Achieves 77% Year-Over-Year Increase in Revenue to $2.9 Million for the Second Quarter of 2023
Gross profit increases 178% compared to the same period last year New online store providing greater interaction with dentists and...